NCBP1 and Associated Diseases
Creative Biolabs devotes to research in the field of gene therapy for more than ten years. With our well-trained scientists and excellent platforms, we believe that all your projects associated with gene therapy can be treated properly by our one-stop customer services for all your purposes.
Overview of NCBP1
In humans, nuclear cap binding protein subunit 1 (NCBP1, also known as NCBP 80 KDa Subunit) is a protein encoded by NCBP1. NCBP1 is a component of the nuclear cap-binding protein complex (CBC), which is an RNA-binding protein. CBC involves a series of cellular processes such as pre-mRNA splicing, nonsense-mediated mRNA decay, and translational regulation by binding to the monomethylated 5' cap of nascent pre-mRNA in the nucleoplasm. Besides, CBC containing NCBP1 can also promote 3'-end processing and RNA nuclear export.
NCBP1 in Disease
Ectopic expression of NCBP1 is associated with cassava brown streak disease in plants and cancers such as lung cancer and breast cancer.
- Lung cancer
NCBP1-CUL4B oncoprotein axis is linked to lung cancer progression. Lung cancer is one of the most frequent cancer types with a high correlation with tumor-associated deaths worldwide. It is reported that silencing of NCBP1 leads to cell growth reduction of HeLa cells. Compared with non-lung cancer tissues, upregulated expression of NCBP1 can be identified in lung cancer tissues, together with several lung cancer cell lines. In lung cancer cells, overexpression of NCBP1 promotes cell growth, wound healing, migration, and epithelial-mesenchymal transition, while knockdown of NCBP1 can reverse it. CUL4B, as a downstream target gene of NCBP1, can be upregulated by NCBP1 in NSCLC. Silence of CUL4B will reverse the tumorigenesis of lung cancer cells caused by NCBP1. Taken together, NCBP1-CUL4B sheds new light on the treatment of lung cancer.
Fig.1 High expression of NCBP1 exists in lung cancer tissue than in adjacent tissue. (Zhang, 2019)
- Breast cancer
Elevated expression of NCBP1 is related to the basal subtype of breast cancer (BC). Classification of disease subtypes will enhance diagnostic capabilities and the acquisition of prognostic information. The subtypes of human BC include basal or basal-like, luminal A, luminal B, and HER2+. According to the microarray data, transcriptome-wide high expression of NCBP1 can be observed in basal-like BC patients. Upregulated NCBP1 expression predicts better overall survival. Thus, NCBP1 primary tumor expression can distinguish the basal subtype of BC from other subtypes and can be a positive prognostic indicator in basal BC patients.
With extensive experience and advanced equipment in the field of gene therapy, Creative Biolabs is professional in every process of gene therapy and we are certainly sure that we can speed up the progress of your project and solve your questions. Please feel free to contact us for more details about your NCBP1 project.
References
- Zhang, H.; et al. NCBP1 promotes the development of lung adenocarcinoma through up‐regulation of CUL4B. J Cell Mol Med. 2019, 23: 6965–6977.
- Mamoor, S. Elevated NCBP1 expression distinguishes basal-like human breast cancer. 9.
